U.S. Rep. Thomas Marino, R-Pennsylvania, hadn’t even gotten a U.S. Senate confirmation hearing before he withdrew his name for consideration as President Donald Trump’s drug czar.
The move on Tuesday came two days after a bombshell from The Washington Post/”60 Minutes” report about the congressman’s role as chief advocate for a 2016 federal law that weakened the U.S. Drug Enforcement Administration’s control over opioid distributors. These middlemen between the pharmaceutical manufacturers and retail pharmacies are suspected of being instrumental in the prescription painkiller abuse epidemic ravaging the country, whistleblowers and others in the joint investigation said.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
